Figure 2 - Comparison of the observed costs of switching to PEG-EPO and expected costs according to PEG-EPO dosage

(A) Comparison between the cost of previous treatment with non-PEGylated ESA and observed (P>.05) and expected (P<.0001) costs of treatment with PEG-EPO. (B) Cost comparison between treatment with darbepoetin and observed (P<.001) and expected treatment with PEG-EPO. (C) Cost comparison between treatment with epoetin beta and observed (P<.0001) and expected cost of treatment with PEG-EPO. Expected dosage was calculated based on the drug leaflet, and costs are expressed in MSP (Euros/patient/month). ESA: erythropoiesis-stimulating agents; CKD: chronic kidney disease; PEG-EPO: methoxy polyethylene glycol-epoetin beta.